<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04889924</url>
  </required_header>
  <id_info>
    <org_study_id>PR148/21</org_study_id>
    <nct_id>NCT04889924</nct_id>
  </id_info>
  <brief_title>ALND vs RDT in Positive Sentinel Node After Neoadjuvant Therapy</brief_title>
  <acronym>ADARNAT</acronym>
  <official_title>Axillary Lymph Node Dissection Versus Axillary Radiotherapy in Patients With Positive Sentinel Node After Neoadjuvant Therapy: A Multicenter Randomized Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the case of primary surgery, in patients with sentinel node involvement, it has already&#xD;
      been shown that omitting axillary lymph node dissection (ALND), often combining axillary&#xD;
      radiotherapy (RT), does not worsen the prognosis and does significantly reduce the appearance&#xD;
      of lymphedema. However, patients who have received neoadjuvant systemic treatment cannot&#xD;
      benefit from this option, even though in the majority of those who have responded well to&#xD;
      treatment, a residual disease in the armpit is low, but there are no studies yet published&#xD;
      that supports the possibility of not performing lymphadenectomy.&#xD;
&#xD;
      The primary endpoint of this study is to assess whether the irradiation of the axilla&#xD;
      concerning axillary lymph node dissection is not inferior in recurrences and overall&#xD;
      survival, in patients with positive sentinel lymph node (SN) after neoadjuvant systemic&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, open-label, parallel-assigned, multicenter, phase III study. The&#xD;
      estimated sample size is 1.666 patients, over 5 years. Patients will be stratified and&#xD;
      analyzed independently according to the neoadjuvant treatment regimen, whether chemotherapy&#xD;
      (CT) +/- hormonal therapy (HT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, randomized, multicenter study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>From date of diagnosis until the date of first documented recurrence or death, wichever came first,assessed up to 5 years</time_frame>
    <description>to assess whether the irradiation of the axilla concerning axillary lymph node dissection is not inferior in disease-free survival, in patients with positive sentinel lymph node (SN) after neoadjuvant systemic treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of diagnosis until the date of death from any cause, assessed up to 5 years</time_frame>
    <description>to assess whether the irradiation of the axilla concerning axillary lymph node dissection is not inferior in overall survival, in patients with positive sentinel lymph node (SN) after neoadjuvant systemic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphedema Incidence</measure>
    <time_frame>From date of surgery until the date of first lynphedema apparition, assessed up to 5 years</time_frame>
    <description>Volume difference between both arms (cm^3) above 10%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1666</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Axillary Adenopathy</condition>
  <condition>Radiotherapy Side Effect</condition>
  <condition>Therapy-Associated Cancer</condition>
  <arm_group>
    <arm_group_label>Axillary radiotherapy without lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axillary radiotherapy (level I and II) + level III and supraclavicular +/- internal mammary chain without lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axillary lymph node dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Axillary lymph node dissection + radiotherapy level III and supraclavicular +/- internal mammary chain</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Axillary Radiotherapy</intervention_name>
    <description>Axillary radiotherapy without lymphadenectomy (level I and II) + level III and supraclavicular +/- internal mammary chain</description>
    <arm_group_label>Axillary radiotherapy without lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphadenectomy</intervention_name>
    <description>Axillary Lymph node dissection</description>
    <arm_group_label>Axillary lymph node dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T1-T4b N0-1 at diagnosis and subsidiary of neoadjuvant treatment&#xD;
&#xD;
          -  Post-CT SLN with â‰¤2 macrometastasis&#xD;
&#xD;
          -  If N + pre-neoadjuvant treatment also include micrometastases&#xD;
&#xD;
          -  Post-CT axillary ultrasound, BEDI &lt;4 in all visualized nodes&#xD;
&#xD;
          -  Complete at least 3 months of neoadjuvant chemotherapy and 6 months of endocrine&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory carcinoma or cN2&#xD;
&#xD;
          -  ypN0&#xD;
&#xD;
          -  History of breast surgery for ipsilateral cancer&#xD;
&#xD;
          -  History of other cancer in the last 5 years, except squamous carcinoma of the skin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Laplana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Catala de Oncologia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amparo Garcia-Tejedor, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amparo Garcia-Tejedor, MDPhD</last_name>
    <phone>0034.932607695</phone>
    <phone_ext>2812</phone_ext>
    <email>agarciat@bellvitgehospital.cat</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Amparo Garcia-Tejedor</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

